An interventional study of Intermittent fasting in Metabolic Syndrome, sponsored by Min Xia. Completed at 1 site in China. Open to participants aged 30 Years to 50 Years. Per ClinicalTrials.gov, last updated 2020-05-27.
Sponsored by Min Xia · Not applicable, Interventional, and Prevention
Among 89 studies in Metabolic Syndrome with a site in China — 35 open to participants now, 39 under way, 1 of them phase 3. Metabolic Syndrome · China.
Among the 89 studies in Metabolic Syndrome with a site in China, this one is the 45th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2018, is one of 39 with no phase, and was the 25th registered.
2,116 studies on the registry are indexed under Metabolic Syndrome; 347 are open to participants now.
Browse Metabolic Syndrome studies →35 of the 89 studies in Metabolic Syndrome with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–65
Zhujiang Hospital · Sites in China
Ages 18–60
Liu Yan · Sites in China
Ages 18–65
Hudson Biotech · Sites in China
Ages 18–65
Meihua Ji · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 232 Metabolic Syndrome studies recruiting now, 68 (29%) set no upper age limit and 136 (59%) stop at 75 or younger; 20 take children under 18; 80 take healthy volunteers.
This study: 30 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6 · Phase 4 4
First in 2000; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 60 across 1,572 interventional studies indexed under Metabolic Syndrome.
Median enrollment 143 across the 50 interventional studies, 1,249 across the 39 observational. Of the 39 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 89 have an industry lead sponsor. The 10 most frequent:
Min Xia is the lead sponsor of 3 studies on the registry; none are open to participants now.
Min Xia has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
12 of the studies in Metabolic Syndrome with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05105321Tang YidaCardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP) | 2026-12 |
| NCT07096102Meihua JiEfficacy of a Health Empowerment Theory Based Health Information Literacy Promotion Intervention in Individuals With Metabolic Syndrome | 2026-12-30 |
| NCT07327684Peking Union Medical College HospitalPhotoacoustic/Ultrasound Imaging of Brown Adipose Tissue Activity | 2026-12-31 |
| NCT07822763First Affiliated Hospital of Chongqing Medical UniversityPreoperative Oral Carbohydrate Loading and Gastrointestinal Recovery After Bariatric Surgery in Metabolic Syndrome | 2027-01 |
| NCT07505745Hudson BiotechMOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity | 2027-02-14 |
Add all 12 to your calendar (.ics) → With an account.
Among the 89 studies in Metabolic Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The survey is designed to investigate whether 8 weeks of discrete two-day intermittent fasting per week will impact gut microbiota and cardiovascular risks of metabolic syndrome subjects.
Intermittent fasting was demonstrated to optimize energy metabolism and promote health. However, the benefits of intermittent fasting to gut microbiota are remain unclear. Further evidence is needed in understanding the effects of intermittent fasting to gut microbiota and cardiovascular risks in subjects with metabolic syndrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Central obesity: waist circumference ≥90 cm in males or ≥80 cm in females; plus any two of the following four conditions:
Exclusion Criteria:
two nonconsecutive days of 75% diet energy restriction per week for 8 weeks
Behavioral: Intermittent fasting
maintain the energy intake as usual
The intervention of two nonconsecutive days of 75% energy restriction per week for 8 weeks
BMI
BMI(weight in kilograms, height in meters and BMI in kg/m\^2)
Time frame: 8 weeks
Body fat mass
Body fat mass (kg)
Time frame: 8 weeks
systolic pressure
systolic pressure(mmHg)
Time frame: 8 weeks
diastolic pressure
diastolic pressure(mmHg)
Time frame: 8 weeks
gut microbiota composition
gut microbiota composition at different levels of classification determined by 16s rRNA pcr
Time frame: 8 weeks
plasma IL-6
plasma interleukin 6 (pg/mL)
Time frame: 8 weeks
plasma TNF-α
plasma TNF-α (pg/mL)
Time frame: 8 weeks
plasma sCD40L
plasma soluble CD40 ligand (ng/mL)
Time frame: 8 weeks
plasma leptin
plasma leptin (ng/mL)
Time frame: 8 weeks
plasma adiponectin
plasma adiponectin (μg/mL)
Time frame: 8 weeks
plasma MDA
plasma malondialdehyde (nmol/mL)
Time frame: 8 weeks
plasma oxLDL
plasma oxidative LDL (mU/L)
Time frame: 8 weeks
plasma total nitrate
plasma total nitrate (mmol/L)
Time frame: 8 weeks
plasma AMDA
plasma asymmetric dimethylarginine (ng/mL)
Time frame: 8 weeks
plasma VCAM-1
plasma vascular cell adhesion protein 1 (ng/mL)
Time frame: 8 weeks
plasma vWF
plasma Von Willebrand factor (U/mL)
Time frame: 8 weeks
metabolic pathway of gut microbiota
metabolic pathway of gut microbiota determined by 16s rRNA pcr
Time frame: 8 weeks
serum LDL-cholesterol
serum LDL-cholesterol(mmol/L);
Time frame: 8 weeks
serum HDL-cholesterol
serum HDL-cholesterol (mmol/L);
Time frame: 8 weeks
serum triglyceride
serum triglyceride (mmol/L)
Time frame: 8 weeks
serum Apo B/apo A1
serum Apo B/apo A1
Time frame: 8 weeks
serum glucose
serum glucose (mmol/L)
Time frame: 8 weeks
serum insulin
serum insulin (mU/L)
Time frame: 8 weeks
serum total cholesterol
serum total cholesterol (mmol/L)
Time frame: 8 weeks
Plan to share: No
Ran from Jun 2018 to primary completion in May 2019, 11 months.
Of 625 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 11 months is below that.
Counting every sponsor, half of 675 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Min Xia